29.07 
0.04(0.14%) 2:29PM EDT - Nasdaq Real Time Price
| Prev Close: | 29.11 |
|---|
| Open: | 28.90 |
|---|
| Bid: | 29.01 x 2200 |
|---|
| Ask: | 29.02 x 15500 |
|---|
| 1y Target Est: | 31.47 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 28.68 - 29.11 |
|---|
| 52wk Range: | 21.40 - 31.15 |
|---|
| Volume: | 24,798,441 |
|---|
| Avg Vol (3m): | 33,843,100 |
|---|
| Market Cap: | 206.20B |
|---|
| P/E (ttm): | 13.89 |
|---|
| EPS (ttm): | 2.09 |
|---|
| Div & Yield: | 0.96 (3.30%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Pfizer Discontinues Its Inotuzumab Evaluation and 2 Other Dow Movers to Watchat Wall St. Cheat Sheet(Fri 1:55PM EDT)
- Midday Glance: Pharmaceuticals companiesAP(Fri 1:17PM EDT)
- BofA Looks For Branch Buyers, Pfizer’s Early Spinoff of Zoetis, and 2 More Hot Stocksat Wall St. Cheat Sheet(Fri 11:46AM EDT)
- [video] Seib & Wessel: The IRS Just Won’t Go Awayat MarketWatch(Fri 10:44AM EDT)
- Early Glance: Pharmaceuticals companiesAP(Fri 10:33AM EDT)
- [$$] Pfizer Set for Higher Earnings Per Shareat Barrons.com(Fri 6:30AM EDT)
- Pfizer Has Potential To Grow Despite Decreasing Salesat Seeking Alpha(Fri 2:23AM EDT)
- Five Key Things About the SAC Insider Caseat Bloomberg(Fri 12:00AM EDT)
- Pfizer Halts Inotuzumab StudyZacks(Thu, May 23)
- Final Glance: Pharmaceuticals companiesAP(Thu, May 23)
- J&J expects 10-plus new drug applications by 2017AP(Thu, May 23)
- 5 Stalwarts Loved by Advanced Investment Partnersat Motley Fool(Thu, May 23)
- 3 Stocks Dragging In The Drugs Industryat TheStreet(Thu, May 23)
- Another Look At Marketing Vs. R&D In Pharmaat Seeking Alpha(Thu, May 23)
- J&J: We're Creaming Medivation, Boehringer, Bristol And Pfizerat Forbes(Thu, May 23)
Key Statistics
| Forward P/E (1 yr): | 12.35 |
|---|
| P/S (ttm): | 3.58 |
|---|
| Ex-Dividend Date: | 08-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.21 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.58 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | 4.78 |
|---|
Business Summary
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care phys...
View More